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Schieber et al. demonstrate that a specific gut microbiota bacterial strain induces a host-mediated
protection mechanism against inflammation-driven wasting syndrome. This salutary effect confers
a net survival advantage against bacterial infection, without interfering with the host’s pathogen
load, revealing that host-microbiota interactions regulate disease tolerance to infection.Figure 1. Protective Effect of E. coli O21:H+ against Bacterial-Infection-Driven Muscle
Atrophy
At steady state, E. coliO21:H+ remains in the gut lumen. However, upon bacterial infections, E. coliO21:H+
translocates across the gut epithelial barrier and accumulates specifically in white adipose tissue. This
occurs via an unknown mechanism that does not require disruption of the intestinal barrier. Once in white
adipose tissue, E. coli O21:H+ is sensed by the Nlrc4 inflammasome (presumably expressed in resident
macrophages; Mø?). This triggers the production of IL-1b and IL-18, possibly acting synergistically to
induce IGF-1 production in white adipose tissue and sustain systemic levels of IGF-1 during bacterial
infections. IGF-1 signaling via PI3K/Akt activation in muscle cells prevents the upregulation of atrophy
associated programs involving the muscle-specific E3 ubiquitin ligases Murf1 and Atrogin1 and leading to
muscle wasting. This tissue damage control mechanism confers disease tolerance to bacterial infections.Immune-driven resistance mechanisms
are usually perceived as the central de-
fense strategy preventing the patholog-
ical outcome of infections. We now
realize, however, that additional defense
strategies are required to achieve this
goal (Medzhitov et al., 2012). These
include an evolutionary conserved de-
fense strategy known as disease toler-
ance, which preserves host homeostasis
during infection without interfering with
the host’s pathogen load (Medzhitov
et al., 2012). The study by Schieber
et al. (2015) published in Science
highlights how host/microbiota interac-
tions manipulate this defense strategy
to confer host protection against bacte-
rial infections and ultimately preserve
homeostasis.
There is now a growing body of experi-
mental evidence to suggest that tissue
damage control mechanisms (Soares
et al., 2014) play a central role in sustaining
disease tolerance to viral (Rodrigue-Ger-
vais et al., 2014), bacterial (Larsen et al.,
2010), or protozoan (Ferreira et al., 2011;
Ra˚berg et al., 2007) infections. While host
microbiota/interactionsareknown to regu-
late immune-driven resistance mecha-
nisms against viral (Ichinohe et al., 2011),
bacterial (Cash et al., 2006), or protozoan
infections (Yilmaz et al., 2014), whether
this was also the case for tissue damage
control mechanisms regulating disease
tolerance to these infections remained
unknown.
Schieber et al. (2015) demonstrate that
a specific bacterial member of the gut
microbiota, namely Escherichia coli
(E. coli) O21:H+, confers a strong survival
advantage against enteric and lung bac-
terial infections in mice. This occurs
without interfering with pathogen growth
(i.e., host pathogen load), revealing thatE. coli O21:H+ confers disease tolerance
to bacterial infections.
The mechanism via which the protec-
tive effect of E. coli O21:H+ is exerted in-
volves sensing of this microbiota compo-
nent by a host inflammasome signaling
platform containing the NOD-like receptor
(NLR) family CARD domain-containing
protein 4 (Nlrc4) (Figure 1). While engage-
ment of the Nlrc4 inflammasome was well
known to trigger the cleavage and secre-
tion of interleukin (IL)-18 and IL-1b, the au-
thors now show that IL-18 and, to a lesser
extent, IL-1b are critical to maintain sys-
temic levels of insulin-like growth factor-
1 (IGF-1) during bacterial infections. ThisCell 163, Nois required to activate a downstream
signal transduction pathway in muscle
cells, involving the Phosphoinositide
3-kinase (PI3K)/Akt and antagonizing
muscle wasting via a process that re-
presses the expression of the E3 ubiquitin
ligases Atrogin-1 and Murf1 (Figure 1).
This tissue damage control mechanism
prevents the development of wasting syn-
drome and accounts for the survival
advantage conferred by E. coli O21:H+
against bacterial infections (Figure 1).
Surprisingly, the protective effect ex-
erted by E. coli O21:H+ requires its active
translocation from the gut into white adi-
pose tissue. The mechanism via whichvember 19, 2015 ª2015 Elsevier Inc. 1057
this occurs is not yet established but is
shown to act independently of the host
Nlrc4 inflammasome. As a final note, the
study by Schieber et al. (2015) suggests
that manipulation of the IGF-1/PI3K/Akt/
Atrogin-1;Murf1 signaling transduction
pathway may be a valuable therapeutic
approach to induce tissue damage con-
trol and to confer disease tolerance to
bacterial infections. This should be partic-
ularly relevant to the treatment of severe
sepsis, given the relative contribution of
muscle wasting to the overall morbidity
and mortality of this infectious disease.
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